BACKGROUND: Maternal @entity565 is a risk factor for @entity565 in offspring; however, transmission of the risk for @entity56 without direct offspring sensitization has not been explored. OBJECTIVE: To determine whether offspring from mothers with ovalbumin (OVA)-sensitized @entity565 would develop @entity1030 at first-ever exposure to OVA and whether preconception maternal treatment with the Antiasthma Simplified Herbal Medicine Intervention (ASHMI) or @entity619 ( @entity9170 ) could modify this risk in offspring. METHODS: Female BALB/c @entity19 (F0) with OVA-induced @entity565 were generated using established protocols. @entity19 with @entity565 were treated with ASHMI, @entity9170 , or water for 6 to 7 weeks. Naive @entity19 served as controls. Subsequently, @entity19 were mated. Twelve-day-old F1 offspring received 3 consecutive intranasal low- or high-dose OVA exposures without sensitization. Forty-eight hours later, @entity32 , mucus hypersecretion, serum antibodies, and cytokines were evaluated. RESULTS: Offspring from OVA-sensitized mothers, but not naive mothers, showed eosinophilic and neutrophilic @entity32 , and @entity1373 after OVA exposure and he presence of OVA-specific @entity6527 and @entity9749 . Offspring of ASHMI- and @entity9170 -treated mothers showed @entity32 and mucus hypersecretion after low-dose OVA (P < .05-.001 for the 2 comparisons vs offspring of OVA/Sham mothers). Offspring of ASHMI-treated, but not @entity9170 -treated, mothers were protected after the high-dose OVA challenge (P < .05-.01 vs offspring OVA/Sham). Maternal ASHMI therapy was associated with increased @entity9749 (P < .01 vs offspring of OVA/Sham mothers) and decreased bronchoalveolar lavage fluid @entity15891 and eotaxin-1 levels (P < .01 and P < .05, respectively, vs offspring of OVA/Sham mothers). CONCLUSION: Offspring of mothers with OVA-induced @entity565 developed @entity32 and mucus to first-ever OVA exposure without prior sensitization. Maternal therapy with ASHMI was superior to @entity9170 in decreasing offspring susceptibility to @entity1030 and could be a strategy to lower @entity565 prevalence.

Maternal Antiasthma Simplified Herbal Medicine Intervention therapy prevents XXXX and modulates pulmonary innate immune responses in young offspring @entity19 .

@entity32 :: ('MESH:D007249', 'Disease') :: ['decreased airway inflammation', 'airway inflammation'] @entity9170 :: ('D003907', 'Chemical') :: ['DEX'] @entity19 :: ('10090', 'Species') :: ['mice', 'Mice'] @entity565 :: ('MESH:D001249', 'Disease') :: ['asthma'] @entity1373 :: ('MESH:D006965', 'Disease') :: ['mucus hyperplasia'] @entity6527 :: ('105243590', 'Gene') :: ['IgG1'] @entity15891 :: ('14825(Tax:10090)', 'Gene') :: ['CXCL-1'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone'] @entity56 :: ('MESH:D004342', 'Disease') :: ['allergic asthma'] @entity1030 :: ('MESH:D029424', 'Disease') :: ['airway disease'] @entity9749 :: ('668478(Tax:10090)', 'Gene') :: ['IgG2a']
@entity32 :: (MESH:D007249,Disease) :: ['airway inflammation']
